Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. Fertil Steril 2017 Sep;108(3):426-441
Date
09/04/2017Pubmed ID
28865539DOI
10.1016/j.fertnstert.2017.06.026Scopus ID
2-s2.0-85028504796 (requires institutional sign-in at Scopus site) 132 CitationsAbstract
Metformin alone compared with placebo increases the ovulation rate in women with polycystic ovary syndrome (PCOS) but should not be used as first-line therapy for anovulation because oral ovulation induction agents such as clomiphene citrate or letrozole alone are much more effective in increasing ovulation, pregnancy, and live-birth rates in women with PCOS. There is fair evidence that metformin alone does not increase rates of miscarriage when stopped at the initiation of pregnancy and insufficient evidence that metformin in combination with other agents used to induce ovulation increases live-birth rates.
Author List
Practice Committee of the American Society for Reproductive Medicine. Electronic address: ASRM@asrm.org, Practice Committee of the American Society for Reproductive MedicineAuthor
Jay I. Sandlow MD Chair, Professor in the Urologic Surgery department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
ComorbidityEvidence-Based Medicine
Female
Humans
Infertility, Female
Metformin
Ovulation Induction
Polycystic Ovary Syndrome
Practice Guidelines as Topic
Pregnancy
Pregnancy Outcome
Prevalence
Risk Factors
Treatment Outcome
United States